Literature DB >> 12960837

Highly active antiretroviral therapy in resource-poor settings: the experience of Médecins Sans Frontières.

Jean-Michel Tassie1, Elisabeth Szumilin, Alexandra Calmy, Eric Goemaere.   

Abstract

We describe the short-term results of highly active antiretroviral therapy (HAART) in seven projects in low and middle income countries. A total of 743 adults were included, and clinical, immunological and virological responses were analysed. At 6 months, outcomes were similar to those observed in western countries, and the probability of remaining on treatment was 94%. The challenge now is to extend access to HAART to the millions in urgent need.

Mesh:

Substances:

Year:  2003        PMID: 12960837     DOI: 10.1097/00002030-200309050-00023

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  20 in total

1.  Immune reconstitution syndrome after highly active antiretroviral therapy in human immunodeficiency virus-infected thai children.

Authors:  Thanyawee Puthanakit; Peninnah Oberdorfer; Noppadon Akarathum; Pornphun Wannarit; Thira Sirisanthana; Virat Sirisanthana
Journal:  Pediatr Infect Dis J       Date:  2006-01       Impact factor: 2.129

2.  From treatment to prevention: the interplay between HIV/AIDS treatment availability and HIV/AIDS prevention programming in Khayelitsha, South Africa.

Authors:  Nomi C Levy; Rebecca A Miksad; Oliver T Fein
Journal:  J Urban Health       Date:  2005-07-27       Impact factor: 3.671

3.  Evaluation of antiretroviral therapy results in Blantyre, Malawi.

Authors:  J J van Oosterhout; N Bodasing; J J Kumwenda; C Nyirenda; J Mallewa; P R Cleary; M P de Baar; R Schuurman; D M Burger; E E Zijlstra
Journal:  Malawi Med J       Date:  2005-12       Impact factor: 0.875

4.  How HIV treatment could result in effective prevention.

Authors:  Kartik K Venkatesh; Mark N Lurie; Kenneth H Mayer
Journal:  Future Virol       Date:  2010-07       Impact factor: 1.831

5.  Anthropometric and immunological success of antiretroviral therapy and prediction of virological success in west African adults.

Authors:  Eugène Messou; Delphine Gabillard; Raoul Moh; André Inwoley; Souleymane Sorho; Serge Eholié; François Rouet; Catherine Seyler; Christine Danel; Xavier Anglaret
Journal:  Bull World Health Organ       Date:  2008-06       Impact factor: 9.408

6.  Determinants of retention in care in an antiretroviral therapy (ART) program in urban Cameroon, 2003-2005.

Authors:  Landry Tsague; Sinata S Koulla; Alain Kenfak; Charles Kouanfack; Mathurin Tejiokem; Therese Abong; Madeleine Mbangue; Yacouba Njankouo Mapoure; Claudine Essomba; Jembia Mosoko; Regis Pouillot; Louis Menyeng; Helene Epee; Carno Tchuani; Anne Cecile Zoung-Kanyi; Lucienne Assumpta Bella; Leopold Zekeng
Journal:  Pan Afr Med J       Date:  2008-07-04

7.  Mapping modifiers affecting muscularity of the myostatin mutant (Mstn(Cmpt-dl1Abc)) compact mouse.

Authors:  László Varga; Géza Müller; Gyula Szabó; Orsolya Pinke; Edit Korom; Balázs Kovács; László Patthy; Morris Soller
Journal:  Genetics       Date:  2003-09       Impact factor: 4.562

8.  Dynamic changes in the distribution of a satellite homologous to intergenic 26-18S rDNA spacer in the evolution of Nicotiana.

Authors:  K Y Lim; K Skalicka; B Koukalova; R A Volkov; R Matyasek; V Hemleben; A R Leitch; A Kovarik
Journal:  Genetics       Date:  2004-04       Impact factor: 4.562

9.  Estimating the capacity for ART provision in Tanzania with the use of data on staff productivity and patient losses.

Authors:  Stefan Hanson; Anna Thorson; Hans Rosling; Claes Ortendahl; Claudia Hanson; Japhet Killewo; Anna Mia Ekström
Journal:  PLoS One       Date:  2009-04-17       Impact factor: 3.240

10.  Effectiveness of antiretroviral therapy and development of drug resistance in HIV-1 infected patients in Mombasa, Kenya.

Authors:  Kim Steegen; Stanley Luchters; Kenny Dauwe; Jacqueline Reynaerts; Kishor Mandaliya; Walter Jaoko; Jean Plum; Marleen Temmerman; Chris Verhofstede
Journal:  AIDS Res Ther       Date:  2009-06-16       Impact factor: 2.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.